2'-O-没食子酰金丝桃苷预防甲状腺眼病组织重塑:作为促甲状腺激素受体拮抗剂的前景
本研究从FDA已批准药物中通过结构虚拟筛选发现2'-O-没食子酰金丝桃苷(2'-O-GH)为潜在促甲状腺激素受体(TSHR)拮抗剂,并在甲状腺眼病(TED)眼眶成纤维细胞(OFs)中评估其效应。2'-O-GH剂量依赖性减少TSHR刺激抗体M22诱导的cAMP产生及CREB磷酸化,并抑制TED-OF的增殖、脂肪生成、透明质酸产生及纤维化分化。作者认为2'-O-GH通过抑制TSHR激活对TED组织重塑具有预防潜力。
要点
- 2'-O-GH剂量依赖性降低M22刺激的cAMP及CREB磷酸化,该效应可被持续激活的TSHR突变(L629F)逆转。
- 2'-O-GH减少TED-OF脂质积累并下调关键脂肪生成标志物,同时改善脂肪生成过程中的透明质酸产生。
- 2'-O-GH抑制TGF-β1刺激的TED-OF伤口闭合和纤维化分化,并阻止TED-OF增殖。
核心结论
- 2'-O-GH通过抑制TSHR激活对增殖、分化和透明质酸沉积发挥抑制作用,有望预防TED组织重塑,提示其潜在治疗价值。
研究设计与样本
- 从FDA已批准药物中通过结构虚拟筛选(SBVS)鉴定潜在TSHR拮抗剂,并评估其对TED-OF的影响。
- 脂肪组织来源于伴或不伴TED的患者,分离的OFs在增殖培养基中培养或在二维/三维模型中刺激进行脂肪生成/纤维化分化。
- OFs用2'-O-GH(0、5、20和50 μM)处理。
主要发现
- 2'-O-GH剂量依赖性减少TSHR刺激单克隆自身抗体M22诱导的cAMP产生及后续CREB磷酸化,该效应被持续激活的TSHR突变(L629F)逆转。
- 2'-O-GH减少TED-OF脂质积累并下调关键脂肪生成标志物,同时改善脂肪生成过程中的透明质酸产生。
- 2'-O-GH抑制TGF-β1刺激的TED-OF伤口闭合和纤维化分化。
- 2'-O-GH阻止TED-OF增殖。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Thyroid eye disease (TED) is a challenging condition owing to relentless orbital tissue remodeling, with thyrotropin receptor (TSHR) in orbital fibroblasts (OFs) serving as a promising therapeutic target. OBJECTIVE: This study seeks to discover potential TSHR inhibitors among US Food and Drug Administration (FDA)-approved drugs and evaluate their effects on TED-OFs. METHODS: Adipose tissues were sourced from the patients with or without TED. Isolated OFs were cultivated in proliferation medium or stimulated for adipogenic/fibrotic differentiation in 2-dimensional/3-dimenstional models, treated with 2'-O-galloylhyperin (2'-O-GH) (0, 5, 20, and 50 μM). Using structure-based virtual screening (SBVS), potential TSHR antagonists were identified. Cellular proliferation was analyzed by 5-ethynyl-2'-deoxyuridine (EdU) incorporation, flow cytometry, and spheroid size. Adipogenesis was determined by Oil Red O staining, Western blot, and immunofluorescence (IF). Fibrosis was assessed using wound-healing assays, Western blot and IF. Cyclic adenosine monophosphate (cAMP), hyaluronan (HA), and cytokine were quantified by enzyme-linked immunosorbent assay. RESULTS: Herein, the FDA-approved drug 2'-O-GH dose-dependently decreased cAMP production and the subsequent cAMP-response element binding protein (CREB) phosphorylation stimulated by a TSHR-stimulating monoclonal autoantibody M22, which was reversed by a consistently activated mutation of TSHR (L629F). As expected, 2'-O-GH attenuated lipid accumulation in TED-OFs, along with downregulation of key adipogenic markers, and 2'-O-GH ameliorated HA production during adipogenesis. Notably, 2'-O-GH dampened wound closure and fibrotic differentiation of TED-OF stimulated by transforming growth factor beta 1. Correspondingly, proliferation of TED-OFs was halted by 2'-O-GH. CONCLUSION: 2'-O-GH is promising for prevention of tissue remodeling of TED by exerting inhibitory effects on proliferation, differentiation, and HA deposition by inhibiting TSHR activation, implying its potential therapeutic value for TED.
引用
- Guo Y, Liu B, Liang W, et al. 2'-O-Galloylhyperin Prevents Tissue Remodeling in Thyroid Eye Disease: Prospects as a Thyrotropin Receptor Antagonist. J Clin Endocrinol Metab. 2025. PMID: 39673421. doi:10.1210/clinem/dgae732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。